Diagnostic tests based on next-generation sequencing (NGS), 5 including gene-panel, exome, and wholegenome sequencing, are routinely performed worldwide. Although the technical validity of NGS-based tests continues to improve rapidly, the community is working to demonstrate the clinical validity and utility of these methods, which largely depend on our ability to interpret all sequence variants in a thorough, reproducible, timely, and clinically relevant manner. Accurately interpreting variants is challenging. The large volume of variants; the lack of curated information regarding the relationship between variants, gene functions, and clinical consequences; and the lack of consistent roles that capture all aspects of a variant's impact on the normal functions of a gene product are some of the challenges faced by medical geneticists, genetic counselors, and molecular pathologists specializing in molecular diagnostic services. The American College of Medical Genetics and Genomics (ACMG), the Association for Molecular Pathology, and the College of American Pathologists recently jointly released standards and guidelines for the interpretation of sequence variants (1 ) . This collective effort by society leadership groups and the whole genetics community aims to address the above challenges and represents a milestone in NGS-based diagnostic testing.
The first set of ACMG variant interpretation guidelines was released in 2008, at a time when Sanger sequencing was the main method of single gene variant detection and molecular diagnostic testing (2 ) . In the 2008 version of these guidelines (referred to here as guidelines 1.0), the decision tree for interpreting a sequence variant started with whether a variant was previously reported as causative of the disease and followed with a prediction based on the nature or type of a variant. Because NGS-based tests often detect numerous previously unreported variants, a classification system based on previously reported variants is of very limited use. Furthermore, population-based exome and wholegenome sequencing projects suggest that many previously reported variants are incorrectly classified (3 ). In the new guidelines (referred to here as guidelines 2.0), which were released in April 2015, various types of evidence of variant pathogenicity are factored into the overall assessment of the clinical relevance of each variant. These guidelines, which rely on original evidence of pathogenicity rather than previously classified data, include a semistructured process that strives to unify the classification process so that conclusions reached by different laboratories using the same set of evidence are consistent. Guidelines 2.0 implement a 5-tier classification system that includes likely benign and likely pathogenic categories. This categorization involves a comprehensive evaluation using many lines of evidence rather than only a few. Thus, guidelines 2.0 are a significant upgrade over version 1.0, which is a 3-tier system.
Evidence
The 4 major categories of evidence for variant pathogenicity assessment are briefly described below.
POPULATION EVIDENCE
Publicly available large-scale exome/genome databases provide allele frequency data for the general population. In principle, when a variant is more common than the incidence of a disease, and disease penetrance is taken into consideration, the variant is unlikely to be disease causing. Conversely, when a variant is absent or is present at a low frequency in the general population, the variant is likely to cause disease. However, rarity alone is not sufficient to indicate pathogenicity. To complicate matters, the prevalence and penetrance of diseases are often not well documented. To minimize subjectivity when using frequency data, both the observed and expected allele frequencies for the disorder should be computed. Interestingly, some common variants can be clinically relevant in special settings. For example, a common haplotype in TBX6 (T-box 6) imposes a risk for the scoliosis phenotype, with an odds ratio of 25 (95% CI 2.4 -262.7) in patients with the 16p11.2 deletion, which involves the whole TBX6 gene (4 ). Thus, the allele frequency should be used in the context of co-occurring variants and a specific phenotype.
GENETIC EVIDENCE
Although linkage evidence does not automatically translate into a causal relationship between variants and disease, the higher the level of cosegregation, the stronger the support for a variant-phenotype association. A high logarithm of the odds score supports a gene-level causal relationship, but linkage disequilibrium should be considered when assigning the causal relationship at the variant level. De novo occurrence is a strong indicator of pathogenicity, especially when paternity and maternity are confirmed. However, de novo variants can occur for any gene at a frequency of about 1 per exome (5 ). Thus, additional evidence is required to support pathogenicity for de novo variants.
BIOLOGICAL AND FUNCTIONAL EVIDENCE
Evidence from functional studies is often considered the ultimate confirmation of causal relationships between variants and phenotypes. In reality, however, functional studies often fail to unequivocally demonstrate a causal relationship, because functional assays are often performed in nonhuman systems using proxy readouts rather than directly measuring or observing a specific disease phenotype. Therefore, a thorough understanding of the biology of the disease and mutation mechanisms is important.
INFORMATICS PREDICTION
Software-based prediction has limited utility in the clinical setting and provides only supportive evidence. Whereas functional assays are not widely available in clinical laboratories, software-based prediction, particular for splicing variants, offers useful information and should be implemented.
Interpretation
Variant interpretation is rather complex. Guidelines 2.0 capture the main principles of role-based variant interpretation and render this type of interpretation tractable. However, the guidelines are vague and prone to different interpretations. For example, the guidelines state the following as strong evidence of pathogenicity: "wellestablished in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product (PS3)." However, what constitutes a well-established functional study is not clearly defined. Although the guidelines suggest that "functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well-established," in reality, almost no such "wellestablished" functional assay systems exist, because functional assessment is not part of the routine workflow in diagnostic laboratories. Currently, most variants are classified as variants of uncertain significance (VUSs), which is the least useful classification. However, guidelines 2.0 fail to subclassify variants in the VUS bucket. We believe that delineating VUSs into groups that lean toward benign or pathogenic (thus resulting in a 7-tier system) would be helpful in better assessing the clinical relevance of variants. The relative weight of contradictory lines of evidence and the level of segregation can be used in the VUS subclassification.
In addition, guidelines 2.0 do not deal with other types of variants, such as copy number variants and structural variants, and they do not classify complex alleles when multiple variants occur on 1 allele of a disease gene. Other issues encountered in variant interpretation are briefly discussed below.
EVIDENCE QUERYING
A complete and unbiased querying of existing evidence is a prerequisite for variant classification. This is a timeconsuming step; it could be overwhelming to incorporate all of the literature associated with some variants, especially when dealing with controversial results. Dated reviews and consensus statements by expert groups or Wikipedia-style curation groups may facilitate such querying.
EVIDENCE CURATION
Evaluating the trueness or the confidence levels of evidence is complicated and challenging. Because positive correlations are much more likely to be reported and published than negative correlations, studies using patient cohorts often demonstrate excellent clinical sensitivity, but without data from large control datasets, the clinical specificity is usually poorly evaluated and the available evidence is likely biased. Therefore, the curation process should include a critical evaluation of published studies.
RELIABILITY
The roles and formulations used to classify variants in guidelines 2.0 are empirical. The sensitivity and specificity of the guidelines have not been evaluated. The guidelines correctly identified many caveats associated with each variant's role in disease, but exceptions to each role are numerous and complex, and a deep understanding of the pathomechanisms involved is critical for interpreting the variants. Experience and personal knowledge could make a significant difference in the usefulness of the guideline.
CAUSAL RELATIONSHIP
The causal relationship between variants and clinical phenotypes needs interpretation. The clinical validity of a genetic test is defined by its ability to accurately and reliably identify individuals who have (or will develop) the disorder or phenotype of interest. The ultimate purpose of variant interpretation is to delineate the relationship between variants and clinical phenotypes. Thus, it is necessary to clearly define the phenotype of interest for variant interpretation. Guidelines 2.0 are not helpful in determining whether the variant explains the patient's condition, and the results obtained are often steps away from directly explaining the patient's clinical condition. Although pathogenicity is an intrinsic property of a variant, whether the variant causes a condition is affected by other factors, including co-occurring variants, in a particular individual. The current guidelines deal with variants in isolation and do not consider specific phenotypes. This shortcoming should be addressed in future versions of the guidelines.
Future Steps
To better implement the new guidelines, we propose that well-curated databases, well-defined functional domains and mutational mechanisms, well-established functional test systems designed for clinical significance assessment, and case-level variant databases be made available. Furthermore, both causality and pathogenicity should be considered in future versions of these guidelines. 
